Sunesis Pharmaceuticals Regains NASDAQ Compliance
March 03 2011 - 7:30AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that
it has received notification from The NASDAQ Stock Market that it
has regained compliance with the minimum $1.00 per share bid price
requirement. As per NASDAQ's Listing Rules, to regain compliance,
the Company was required to evidence a closing bid price of $1.00
per share or more for at least ten consecutive days. On March 1,
2011, the closing bid price of the Company's common stock was $1.98
per share, the tenth consecutive day the stock price had closed
above $1.00 per share.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for
the treatment of solid and hematologic cancers. Sunesis has built a
highly experienced cancer drug development organization committed
to advancing its lead product candidate, vosaroxin, in multiple
indications to improve the lives of people with cancer. For
additional information on Sunesis, please visit
http://www.sunesis.com.
The Sunesis Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8773
This press release contains forward-looking statements.
Forward-looking statements are based upon Sunesis' current
expectations. Forward-looking statements involve risks and
uncertainties. Sunesis' actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties related to Sunesis' ability to comply with the
continued listing requirements of and maintain its listing on the
NASDAQ Capital Market, need for substantial additional funding to
complete the development and commercialization of vosaroxin, the
risk that unfavorable economic and market conditions may make it
more difficult and costly to raise additional capital, the risk
that Sunesis' development activities for vosaroxin could be halted
or significantly delayed for various reasons, the risk that
Sunesis' clinical studies for vosaroxin may not demonstrate safety
or efficacy or lead to regulatory approval, the risk that data to
date and trends may not be predictive of future data or results,
the risk that Sunesis' nonclinical studies and clinical studies may
not satisfy the requirements of the FDA or other regulatory
agencies, risks related to the conduct of Sunesis' clinical trials,
risks related to the manufacturing of vosaroxin, and the risk that
Sunesis' proprietary rights may not adequately protect vosaroxin.
Risk factors related to Sunesis and its business are discussed
under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on
Form 10-Q for the quarter ended September 30, 2010 and other
filings with the Securities and Exchange Commission. Sunesis
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals,
Inc.
CONTACT: Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
Historical Stock Chart
From Oct 2023 to Oct 2024